Automate Your Wheel Strategy on VKTX
With Tiblio's Option Bot, you can configure your own wheel strategy including VKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol VKTX
- Rev/Share 0.0
- Book/Share 7.0938
- PB 4.6392
- Debt/Equity 0.0011
- CurrentRatio 25.8604
- ROIC -0.2673
- MktCap 3700564950.0
- FreeCF/Share -1.3603
- PFCF -24.2604
- PE -21.5121
- Debt/Assets 0.0011
- DivYield 0
- ROE -0.1998
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | VKTX | Cantor Fitzgerald | -- | Overweight | -- | $104 | April 29, 2025 |
| Initiation | VKTX | Goldman | -- | Neutral | -- | $30 | April 8, 2025 |
| Initiation | VKTX | Scotiabank | -- | Sector Outperform | -- | $102 | Feb. 13, 2025 |
| Initiation | VKTX | Citigroup | -- | Neutral | -- | $38 | Feb. 7, 2025 |
| Initiation | VKTX | JP Morgan | -- | Overweight | -- | $80 | Sept. 11, 2024 |
News
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.
Read More
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive
With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.
Read More
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Published: July 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Read More
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.
Read More
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Positive
VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with $850M cash and large pivotal trials underway for both injectable and oral VK2735. Viking doesn't need to outperform Lilly or Novo; meeting FDA approval thresholds could secure blockbuster status in a massive, multi-drug market.
Read More
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
VKTX Initiates Phase 3 Study on Obesity Candidate VK2735
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Neutral
Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.
Read More
What's Going On With Viking Therapeutics Stock On Wednesday?
Published: June 25, 2025 by: Benzinga
Sentiment: Positive
Viking Therapeutics, Inc. VKTX on Wednesday initiated the VANQUISH Phase 3 clinical program for VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.
Read More
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Published: June 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential
Published: June 02, 2025 by: Seeking Alpha
Sentiment: Positive
I rate Altimmune a 'Strong Buy' and Viking Therapeutics a 'Buy' for high-risk, long-term investors. ALT's Pemvidutide stands out for its lean mass protection, visceral fat reduction, and potential in multiple metabolic diseases, making it an attractive acquisition target. VKTX's VK2735 offers strong weight loss efficacy and dual formulation flexibility, but faces tough competition and lacks clear differentiation, despite financial stability.
Read More
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock Has More Upside?
Published: May 27, 2025 by: Zacks Investment Research
Sentiment: Positive
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Read More
Viking Therapeutics: Weight-Loss Story Remains Intact
Published: May 22, 2025 by: Seeking Alpha
Sentiment: Positive
Viking Therapeutics remains a promising weight-loss drug biotech due to the enrollment of new promising trials. The weight-loss sector's momentum has faded some, but Eli Lilly and Novo Nordisk have still generated substantial value for shareholders. Viking Therapeutics has upcoming catalysts, including late-July Phase 2 oral data and Phase 3 injectable trial enrollment, potentially driving significant upside in the stock.
Read More
Viking Therapeutics: A High Potential Biotech Play With Manageable Risks
Published: May 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Viking targets massive, validated markets with GLP-1/GIP and THR-β agonists, offering injectable and oral alternatives with promising Phase 2/3 results. Positioned as a second-line, tolerable, patient-friendly treatment in an established space with significant addressable market size. Compared to some other binary bets in big pharma, Viking offers leaner operations, lower complexity, faster trial execution, and less execution risk.
Read More
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Published: May 06, 2025 by: The Motley Fool
Sentiment: Positive
One of the best catalysts for a stock's rise is the withdrawal of a rival. That was an important dynamic behind the double-digit-percentage rise of biotech Viking Therapeutics' (VKTX 0.32%) stock in April.
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
1 Beaten-Down Stock to Buy and Hold for 10 Years
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX 3.44%) was one of the hottest biotech stocks of 2024; its shares soared last year following excellent clinical progress. However, things have been very different in 2025, at least so far: Its stock is down by 35% year to date due to a combination of factors.
Read More
Why Viking Therapeutics Stock Popped Again Today
Published: April 29, 2025 by: The Motley Fool
Sentiment: Positive
Shares of Viking Therapeutics (VKTX 11.41%) jumped 12.5% through 11:40 a.m. ET on Tuesday on further support from Wall Street analysts.
Read More
Why Viking Therapeutics Stock Popped Today
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX 0.40%) stock inched 2.3% higher through 10:20 a.m. ET Monday, and for a most curious reason.
Read More
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?
Published: April 22, 2025 by: Zacks Investment Research
Sentiment: Positive
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Is Viking Therapeutics Stock (VKTX) Nearing A Bottom?
Published: April 21, 2025 by: See It Market
Sentiment: Neutral
With earnings scheduled for the 23rd, Viking Therapeutic's (NASDAQ: VKTX) first-quarter investor call is expected to center around key pipeline updates. The spotlight will be on three clinical candidates: VK2735 (targeting obesity), VK2809 (for non-alcoholic steatohepatitis, or NASH), and VK0214 (for X-linked adrenoleukodystrophy, or X-ALD).
Read More
Viking Therapeutics: A Lot More Compelling After The Meltdown - Initiating Cautious Buy (Rating Upgrade)
Published: April 17, 2025 by: Seeking Alpha
Sentiment: Positive
VKTX's deep selloff from the 2024 heights have been well warranted indeed, given its pre-revenue status and ongoing cash burn, despite the promising GLP-1 candidates. It has also triggered the improved margin of safety and relatively compelling 2030 valuations, despite the recently downgraded forward estimates. This is significantly aided by the improved clarity surrounding VKTX's go-to-market strategy, as the management announces its first supply and manufacturing partnership.
Read More
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Read More
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.
Read More
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Published: April 14, 2025 by: The Motley Fool
Sentiment: Positive
Bad news for Pfizer (PFE 1.07%) turned into good news for Eli Lilly (LLY 2.42%), Novo Nordisk (NVO 2.23%), and Viking Therapeutics (VKTX 8.48%) Monday morning, each of which is rising on Pfizer's latest product announcement.
Read More
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
Published: March 26, 2025 by: Investors Business Daily
Sentiment: Positive
Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study. The post Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study appeared first on Investor's Business Daily.
Read More
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Published: March 19, 2025 by: The Motley Fool
Sentiment: Positive
Viking Therapeutics (VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.
Read More
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
Published: March 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Read More
About Viking Therapeutics, Inc. (VKTX)
- IPO Date 2015-04-28
- Website https://www.vikingtherapeutics.com
- Industry Biotechnology
- CEO Brian Lian
- Employees 45